EBD/BIOPHARM-AMERICA
20.5.2014 16:58:03 CEST | Business Wire | Pressemeddelelse
The seventh annual BioPharm America™ international life science partnering conference will be held September 22–24 at Boston Marriott Copley Place in the center of Boston’s historic Back Bay. The event brings together industry thought leaders and high level executives in the biopharma dealmaking arena to collaborate on and discuss relevant trends and topics.
Several industry leaders commented on trends and topics that will be featured on the BioPharm America program this year.
"This IPO window has been open longer than any in biotech’s history; while it is unclear how long this cycle will continue, it has provided much needed growth capital to support a new generation of emerging biotech companies. In addition, the IPO route has provided a compelling alternative to M&A-driven liquidity. With pharma’s appetite for innovation continuing to be strong, I expect the interplay of the IPO and M&A markets to feature prominently as a hot topic at BioPharm America this year.” - Bruce L. Booth, Partner, Atlas Venture
“The dynamics of the research ecosystem are changing rapidly. At AstraZeneca we are creating a ‘porous’ research environment to actively engage external science. The recent launch of our Open Innovation website provides a broad range of collaborative and ‘co-creation’ possibilities for academics. There will be ongoing discussion at BioPharm America regarding both open innovation and novel partnership paradigms.” - Kumar Srinivasan, VP, Scientific Partnering and Alliances, AstraZeneca
“The recent CoStim acquisition by Novartis turned the spotlight toward a particularly successful scientific collaboration between academic researchers and an entrepreneurial investor group that recognized the need for such assets within big pharma. This is a great demonstration of the new face of academic partnerships and the unique power of the Boston ecosystem.” - Michal Preminger, PhD, MBA , Executive Director, Office of Technology Development, Harvard Medical School
Early academic collaboration is another focus of BioPharm America this year, as it will be a featured program topic and is the focus of an Academic Innovators presentation track.
“Academic research institutions are the nexus for early stage drug discovery collaborations opportunities with life science companies. We have the human genomics data to advance new targets, we have drug discovery capabilities, and we have the expertise. The game has changed and academia is the new innovation breeding ground.” - Leslie Molony, PhD, Senior Director, Business Development, Sanford-Burnham Medical Research Institute Office of Technology Management and Commercialization
More than 900 delegates representing 550 companies from 35 countries participated in BioPharm America 2013. Delegates in 2013 engaged in 2,950 one-to-one partnering meetings and identified 757 potential licensing opportunities.
BioPharm America is produced by EBD Group in collaboration with the Massachusetts Biotechnology Council (MassBio) to facilitate strategic collaborations with leading companies. One-to-one networking at BioPharm America™ is powered by partneringONE® , the leading conference networking solution for the life sciences.
Register before July 18, 2014 to save USD 200. MassBio members receive an additional USD 200 discount by adding the code ‘MassBio’ in the comments field of the online registration form.
Presenting companies should submit an application by June 30, 2014 .
About BioPharm America 2014
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2014 on Twitter: @EBDGroup (hashtag: No. BPA14).
Or join the Life Science Partnering group on partnering360® to kick off your partnering activities before BioPharm America, and throughout the year. partnering360 is a dynamic network of life science industry experts that will enable you to continue the dialogue from your partneringONE meetings at events and identify and connect with new partners anytime, year-round. Join the vibrant community of life science companies on partnering360 today.
Notes to Editors:
Entry to BioPharm America 2014 is free to members of the press, including full access to the partnering system, sessions, press conferences, workshops, and pre-arranged partnering meetings. Visit the BioPharm America conference website at http://www.ebdgroup.com/bpa/registration/press_reg.php for press registration details.
Online Press Kit service for BioPharm America™ 2014 is available to enhance your public relations efforts.
About MassBio
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum ™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140520006346/en/
Contact:
MassBio
Jessica Roche
+1 617 674 5146
jessica.roche@massbio.org
or
EBD
Group
Erin Righetti
+1 760 930 0500
erighetti@ebdgroup.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
PUMA and Salehe Bembury Host Immersive Sound-Inspired Experience ahead of Football’s Biggest Tournament at The Row DTLA5.6.2026 09:59:00 CEST | Press release
Event Celebrated the launch of the PUMA x Salehe Bembury TRVL WEAR Collection and Velum 1 to be worn by PUMA’s 11 Federations this summer Global sports company PUMA and visionary designer Salehe Bembury hosted an immersive experience at The Row DTLA celebrating their collaboration ahead of football's biggest global tournament. The activation transformed the historic venue into a series of interactive environments, offering guests an inside look into the creative world behind the partnership. Set against the backdrop of Los Angeles, the event brought football beyond the pitch and into everyday life through the lens of sound and design. The PUMA x SALEHE BEMBURY collaboration kicks off PUMA’s second chapter of football introductions this summer, following the launch of their 11 national federation kits in March. This more streetwear-oriented launch introduces a bespoke collection of travel wear and goalkeeper kits for PUMA’s 11 national federations in the tournament. This press release f
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 07:00:00 CEST | Press release
Phase 2 RAINBOW study data showed that treatment with nizubaglustat in patients with GM2 gangliosidosis (GM2) and Niemann-Pick type C disease (NPC) reduced disease progression and seizure burdenTopline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacyThe published data further supports the two ongoing registrational Phase 3 studies with nizubaglustat in GM1/GM2 and NPC Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcemen
K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 03:00:00 CEST | Press release
KSGC 2026 provides end-to-end support - from market entry to sustainable growth - positioning Korea as the gateway for Asia expansion South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from ma
Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More4.6.2026 23:46:00 CEST | Press release
The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum